Study details
Enrolling now
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Inmagene LLC
NCT IDNCT07037901ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
220
Study length
about 2.4 years
Ages
18–74
Locations
16 sites in CA, FL, IL +8
About this study
Researchers are testing a treatment called IMG-007 compared to a placebo for adults with moderate-to-severe atopic dermatitis. The trial will last 866 days, and the goal is to enroll 220 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take IMG-007
- 2.Take Placebo
PhasePhase 2
Primary goalMean percent change from baseline in EASI at Week 20
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Mean percent change from baseline in EASI at Week 20
Secondary: Incidence and severity of TEAE including treatment-emergent SAEs, Mean percent change from baseline in EASI at Week 16
Body systems
Dermatology